连续肾脏替代疗法治疗肾衰竭合并顽固性心力衰竭的临床安全性

Clinical Safety of Continuous Renal Replacement Therapy(CRRT)in the Treatment of Renal Failure Combined with Refractory Heart Failure

目的探讨对肾衰竭伴有顽固性心力衰竭患者给予连续肾脏替代疗法(Continuous Renal Replacement Therapy,CRRT)治疗后获得的临床效果以及安全性。方法非随机抽选2020年2月—2023年6月沭阳中兴医院收治的62例肾衰竭伴有顽固性心力衰竭患者,分组依据为治疗方式差异。参照组(31例)采用传统治疗;研究组(31例)采用连续肾脏替代疗法。比较两组合并症患者的电解质水平、生命体征变化、肾功能水平指标以及不良反应总发生率。结果治疗后,与参照组比较,研究组血钠水平、血钾水平更优,收缩压水平、舒张压水平、呼吸次数、心率水平、尿素氮水平以及血肌酐水平更优,差异有统计学意义(P均<0.05);两组不良反应总发生率比较(9.68%vs 6.45%),差异无统计学意义(χ^(2)=0.217,P>0.05)。结论临床对肾衰竭伴有顽固性心力衰竭患者在给予治疗期间,合理采用CRRT方法展开疾病治疗,可改善患者的电解质水平、生命体征变化以及肾功能水平,并且安全性较高。

Objective To investigate the clinical efficacy and safety of continuous renal replacement therapy(CRRT)in patients with renal failure and refractory heart failure.Methods A total of 62 patients with renal failure accompa-nied by refractory heart failure in Shuyang Zhongxing Hospital from February 2020 to June 2023 were non-randomly selected.They were grouped according to differences in treatment methods;reference group(31 cases)received tradi-tional therapy;study group(31 cases)received continuous renal replacement therapy.The electrolyte level,vital signs,renal function level and the total incidence of adverse reactions were compared between the two groups.Results After treatment,compared with the reference group,the blood sodium level and blood potassium level were better in the study group,the systolic blood pressure level,diastolic blood pressure level,respiratory frequency,heart rate level,urea nitrogen level and blood creatinine level were better in the study group,the differences were statistically signifi-cant(all P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(9.68%vs 6.45%)(χ^(2)=0.217,P>0.05).Conclusion In clinical treatment of patients with renal failure accompanied by refractory heart failure,reasonable use of CRRT can effectively improve the electrolyte level,changes in vital signs and renal function of patients,and it is safe.